- Home
- ACAD vs GLOB Comparison
ACAD vs GLOB Comparison
Compare ACAD & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- GLOB
- Stock Information
- Founded
- ACAD 1993
- GLOB 2003
- Country
- ACAD United States
- GLOB Luxembourg
- Employees
- ACAD N/A
- GLOB N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- GLOB EDP Services
- Sector
- ACAD Health Care
- GLOB Technology
- Exchange
- ACAD Nasdaq
- GLOB Nasdaq
- Market Cap
- ACAD 4.3B
- GLOB 4.7B
- IPO Year
- ACAD 2004
- GLOB 2014
- Fundamental
- Price
- ACAD $24.67
- GLOB $55.59
- Analyst Decision
- ACAD Buy
- GLOB Buy
- Analyst Count
- ACAD 21
- GLOB 14
- Target Price
- ACAD $29.30
- GLOB $138.71
- AVG Volume (30 Days)
- ACAD 1.8M
- GLOB 1.5M
- Earning Date
- ACAD 11-05-2025
- GLOB 11-13-2025
- Dividend Yield
- ACAD N/A
- GLOB N/A
- EPS Growth
- ACAD 615.00
- GLOB N/A
- EPS
- ACAD 1.33
- GLOB 2.44
- Revenue
- ACAD $1,018,885,000.00
- GLOB $2,482,415,000.00
- Revenue This Year
- ACAD $14.01
- GLOB $3.90
- Revenue Next Year
- ACAD $11.72
- GLOB $4.14
- P/E Ratio
- ACAD $18.55
- GLOB $22.96
- Revenue Growth
- ACAD 14.41
- GLOB 8.66
- 52 Week Low
- ACAD $13.40
- GLOB $54.36
- 52 Week High
- ACAD $26.65
- GLOB $238.32
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- GLOB 24.21
- Support Level
- ACAD $23.34
- GLOB $56.14
- Resistance Level
- ACAD $25.90
- GLOB $59.00
- Average True Range (ATR)
- ACAD 0.78
- GLOB 2.24
- MACD
- ACAD -0.28
- GLOB -0.31
- Stochastic Oscillator
- ACAD 40.18
- GLOB 8.63
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.